Similar articles

• Correspondence.

  Uparkar M, Maiti A, Natarajan S. Uparkar M, et al. Retina. 2008 Mar;28(3):527; author reply 527-8. doi: 10.1097/IAE.0b013e31815f3c74. Retina. 2008. PMID: 18327151 No abstract available.
• Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.

  Spandau UH, Jonas JB. Spandau UH, et al. Acta Ophthalmol Scand. 2007 May;85(3):340-1. doi: 10.1111/j.1600-0420.2006.00832.x. Acta Ophthalmol Scand. 2007. PMID: 17488467 No abstract available.
• Comparing ranibizumab with bevacizumab.

  Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Biswas P, et al. Ophthalmology. 2011 Mar;118(3):600-600.e2. doi: 10.1016/j.ophtha.2010.10.027. Ophthalmology. 2011. PMID: 21376243 Clinical Trial. No abstract available.
• Antiangiogenic therapy in neovascular age-related macular degeneration.

  Lin RC, Rosenfeld PJ. Lin RC, et al. Int Ophthalmol Clin. 2007 Winter;47(1):117-37. doi: 10.1097/IIO.0b013e31802bd873. Int Ophthalmol Clin. 2007. PMID: 17237677 Review. No abstract available.
• Molecular biology of choroidal neovascularization.

  Lu M, Adamis AP. Lu M, et al. Ophthalmol Clin North Am. 2006 Sep;19(3):323-34. doi: 10.1016/j.ohc.2006.05.001. Ophthalmol Clin North Am. 2006. PMID: 16935207 Review.